At 12 months, the OS rate for patients who received treatment with ipilimumab plus nivolumab was superior to SOC.
nccRCC
Advertisement
Dr. Cheaib discusses outcomes in patients with non-clear cell RCC with tumor thrombus involvement after surgical treatment.
CN may improve OS for patients with metastatic nccRCC compared with systemic therapy alone, especially when combined with IO.
Patients with ccRCC and nccRCC with tumor thrombus have similar survival outcomes after surgical resection.
An exploratory analysis revealed a strong OS advantage associated with a PD-L1 combined positive score higher than 1.
Previous data from the phase II CALYPSO study has demonstrated the efficacy of durvalumab in combination with savolitinib.
Serial ctDNA negativity or clearance was linked to improved PFS compared with persistent ctDNA positivity during treatment.
New data shows patients with nccRCC may benefit from adjuvant therapy at a comparable rate as patients with ccRCC.
In the final segment of this roundtable, the panelists discuss the potential of adjuvant treatments and systemic therapy.
In the fourth part of this roundtable series, the panelists discuss the use of IO/IO and IO/TKI therapy in nccRCC.
In the third segment of this roundtable series, the panelists compare systemic therapy with nephrectomy for nccRCC.
Conference Coverage
The Two Onc Docs review QOL related to doublet ADT with darolutamide, niraparib with abiraterone for mCSPC, and more.
The Two Onc Docs review the 5-year follow-up data on adjuvant pembro and a final analysis on ipi/nivo for metastatic disease.
The Two Onc Docs weigh IO for BCG-refractory NMIBC, ctDNA monitoring for patients receiving gem/cis for MIBC, and more.
Dr. Machaalani highlights his study that evaluated the association between circulating KIM-1 and mRCC tumor biology.
Dr. James showcases an MMAI model to identify benefit from 2nd-generation ARPIs in hr/nm PCa patients from STAMPEDE.
Drs. Necchi and Tawagi break down in detail the first results of SURE-02 in patients with muscle-invasive bladder cancer.
Advertisement
Advertisement
Trending
The Two Onc Docs review the 5-year follow-up data on adjuvant pembro and a final analysis on ipi/nivo for metastatic disease.
Dr. Machaalani highlights his study that evaluated the association between circulating KIM-1 and mRCC tumor biology.
Dr. McGregor shares the opening of the STRIKE trial, which investigates adding tivo to pembro in the mRCC adjuvant setting.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.